New strategies in endometrial cancer: Targeting the PI3K/mTOR pathway-The devil is in the details

Clinical Cancer Research

Volumn 19, Issue 19, 2013, Pages 5264-5274

  Myers, Andrea P ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; APITOLISIB; BEVACIZUMAB; BUPARLISIB; CARBOPLATIN; EVEROLIMUS; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; PACLITAXEL; PF 04691502; PF 05212384; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPALOG; RAPAMYCIN; RIDAFOROLIMUS; TAMOXIFEN; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 147;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL GROWTH; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84886394046     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0615     Document Type: Article

References (55)

1. Jemal A, Bray F, CenterMM,Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Calle E, Rodriguez C, Walker-Thurmond K, Thun M. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. NEJM 2003;348:1625-38.
4. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134.
5. Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007;25:2983-90.
6. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19.
7. Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1988;332: 644-6.
8. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998;279:710-4.
9. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010;11:9-22.
10. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10: 307-18.
11. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273: 13375-8.
12. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95:29-39.
13. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008;27:5527-41.
14. Ramjaun AR, Downward J. Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle 2007;6: 2902-5.
15. Schultze SM, Hemmings BA, Niessen M, Tschopp O. PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev Mol Med 2012;14:e1.
16. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011;29: 4452-61.
17. The Cancer Genome Atlas Research Network Integrated genomic characterization of endometrial carcinoma. Nature 2013;497: 67-73.
18. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ,Hamm H, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997;6:1383-7.
19. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet 1997;16:64-7.
20. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice. Cancer Res 2000;60: 3605-11.
21. Podsypanina K. Mutation of PTEN/Mmaci in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999;96: 1563-8.
22. Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP, et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 2008;68: 5619-27.
23. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57: 4736-8.
24. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40.
25. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW. PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011;71:4061-7.
26. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011; 17:1331-40.
27. Weigelt B, Banerjee S. Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol 2012;24: 554-63.
28. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011;1:170-85.
29. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
30. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
31. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012;18: 5856-64.
32. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010;116:5415-9.
33. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29:3278-85.
34. Ray-Coquard I, Favier L, Weber B, Roemer-Becuwe C, Bougnoux P, Fabbro M, et al. Everolimus as second-or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer 2013;108:1771-7.
35. Colombo N, McMeekin DS, Schwartz PE, Sessa C, Gehrig PA, Holloway R, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer 2013; 108:1021-6.
36. Mackay H, Welch S, Tsao MS, Biagi JJ, Elit L, Ghatage P, et al. Phase II study of oral ridaforolimus in pateints with metastatic and/or locally advanced recurrent endometrial cancer. J Clin Oncol 29, 2011 (suppl; abstr 5013).
37. Oza A, Poveda A, Clamp A, Pignata S, Scambia G, Del Campo J, et al. A randomized phase II trial of ridaforolimus compared with progestin or chemotherapy in female adult patients with advanced endometrial carcinoma. J Clin Oncol 29, 2011 (suppl; abstr 5009).
38. Tredan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol. 2012 Dec 13. [Epub ahead of print].
39. Meyer LA, Slomovitz BM, Djordjevic B, Galbincea JM, Johnston TA, Munsell M, et al. The search continues: looking for predictive biomarkers for response mTOR inhibition in endometrial cancer. J Clin Oncol 29, 2011 (suppl; abstr 5016).
40. Mackay H, Eisenhauer EA, Kamel-Reid S, Clarke B, Walsh W, Karakasis K, et al. Molecular determinants of outcome with mTOR inhibition in endometrial cancer. J Clin Oncol 30, 2012 (suppl; abstr 5010).
41. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A 2009; 106:4834-9.
42. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al.Genome sequencing identifies a basis for everolimus sensitivity. Science 2012 338:221.
43. Bar-Peled L, Schweitzer LD, Zoncu R, Sabatini DM. Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell 2012;150:1196-208.
44. Robitaille AM, Christen S, Shimobayashi M, Cornu M, Fava LL, Moes S, et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 2013;339: 1320-3.
45. Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013;339:1323-8.
46. Chen S, Bigner SH, Modrich P. High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6. Proc Natl Acad Sci U S A 2001;98:13802-7.
47. Slomovitz BM, Brown J, Johnston A, Mura D, Levenback C, Wolf J, et al. A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 29, 2011 (suppl; abstr 2012).
48. Fleming G, Filiaci V, Hanjani P, Burke JJ, Davidson SA, Leslie KK, et al. Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248.J Clin Oncol 20, 2011 (suppl; abstr 5014).
49. Alvarez EA, Brady WE, Walker JL. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129:22-7.
50. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284: 8023-32.
51. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 2008; 105:17414-9.
52. Myers AP, Broaddus RR, Makker V, Konstantinopoulos P, Drapkin R, Liu JF, et al. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). J Clin Oncol 31, 2013 (suppl;abstr 5524).
53. Shapiro G, LoRusso P, Kwak EJ, Cleary J, Musib L, Jones C, et al. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: a first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J Clin Oncol 29, 2011 (suppl; abstr 3005).
54. Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol 2011;205:518-25.
55. Ju Z, Westin SN, Broaddus RR. PTEN loss is a context dependent determinant of patient outcomes in obese and non-obese endometrioid endometrial cancer patients. J Clin Oncol 31, 2013 (suppl; abstr 5521).